

Melanoma: Assessment and Management - Committee Meeting 9

Date: 21st April 2021

Location: Zoom

Minutes: Final

Committee members present:		
Andrew Molyneux	Chair	Present for all
Guy Burkill	Radiologist	Present for all
Dharmisha Chauhan	Co-opted Pharmacist	Present for all
Susan Cheetham	Lay member	Present for all
Fiona Collier	GP	Present for all
Gillian Godsell	Clinical nurse specialist	Present for all
Sarah Hemington-Gorse	Plastic Surgeon	Present for all
Ian James	Lay member	Present for all
Lynne Jamieson	Histopathologist	Present for all
Stephen Keohane	Dermatologist	Present for all
John Lear	Dermatologist	Present for all
Christine Parkinson	Medical Oncologist	Present for all
Howard Peach	Plastic Surgeon	Present for all
Saskia Reeken	Clinical nurse specialist	Present for all
Myles Smith	General Surgeon	Present for Items 1 - 4
Delia Sworm	Oncology nurse specialist	Present for all
Steven Watkins	Oncologist	Present for all
Sophie Wilne	Co-opted Paediatric Oncologist	Present for all

In attendance:		
Steph Armstrong	NICE Technical Analyst, Health Economics	Present for all
Victoria Axe	NICE Guideline Commissioning Manager	Present for Items 1 – 3, 5 – 6
Becky Chadwick	NICE Project Manager	Present for all
Jeremy Dietz (JD)	NICE Technical Analyst, Health Economics	Present for all
Brett Doble	NICE Technical Analyst, Health Economics	Present for all
Stephen Duffield	NICE Technical Analyst	Present for Item 4 only
Jackie Durkin	NICE Administrator	Present for Item 1 only

Hannah Lomax (HL)	NICE Technical Analyst, Health Economics	Present for all
Tom Jarrett (TJ)	NICE Technical Analyst	Present for all
Judith McBride	NICE Senior Medical Editor	Present for all
Caroline Mulvihill	NICE Technical Analyst	Present for all
Yang Song (<i>observing</i>)	PhD Candidate	Present for all
Sue Spiers	NICE Associate Director	Present for all

Apologies:

William Bolland	GP
Jenny Craven	NICE Information Services

Item 1

- Welcome
- DOIs
- Minutes from previous meetings

Andrew Molyneux (the Chair) welcomed the committee members and attendees to the ninth committee meeting for the 'Melanoma: Assessment and Management' guideline. Apologies were noted as listed above.

Committee members were asked to declare any new interests that had occurred since the last meeting. The following new interests were declared:

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dharmisha Chauhan	Co-opted pharmacist	Direct, Financial	Sanofi – Presentation on quality of life and toxicity management for cemiplimab for non-melanoma skin cancer (cutaneous squamous cell carcinoma)	May 2021	28 th April 2021	28 th April 2021	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Stephen Keohane	Dermatologist	Direct, Financial	Sanofi – Presentation on quality of life and toxicity management for cemiplimab for non-melanoma skin cancer (cutaneous squamous cell carcinoma)	May 2021	28 th April 2021	28 th April 2021	Declare and participate Rationale: Not specific to any particular guideline topic Approved by

							SS
--	--	--	--	--	--	--	----

The minutes from committee meeting 8 were approved as an accurate record of proceedings.

Item 2

- RQ 5.1: further recommendation on localised anticancer treatments

The Chair introduced committee member Myles Smith (MS), who gave a presentation on regional treatment options in relation to RQ 5.1 on localised anticancer treatments.

The Chair thanked MS for his presentation and the committee for their feedback.

Item 3

- RQ 6.3: presentation of evidence and recommendations

Following a short break, the Chair introduced NICE Technical Analyst Tom Jarrett (TJ), who presented on the evidence and recommendations for RQ 6.3: *Should brain imaging be included for people with melanoma who are undergoing body imaging as part of follow-up, and who have no neurological signs or symptoms?* The NICE technical team then asked the committee for input on the wording of palliative care and TVEC recommendations.

The Chair thanked TJ for his presentation and the committee for their feedback.

Item 4

- RQ 3.1 and 4.1: clinical introduction

The Chair introduced committee member Howard Peach, who gave a brief clinical introduction to RQ 3.1: *What are the most effective surgical and histological excision margins for stage 0 to 2 melanoma?* and RQ 4.1: *What is the effectiveness of completion lymphadenectomy for micro metastatic nodal disease in stage 3 melanoma?*

The Chair thanked HP for his presentation and the committee for their feedback.

Item 5

- Presentation of NMA results

The Chair introduced NICE Technical Analyst, Health Economics, Jeremy Dietz, who gave a presentation of the NMA results on effective systemic anticancer treatment for people with stage 4 (+ unresectable stage 3) melanoma.

The Chair thanked JD for his presentation and the committee for their feedback.

Item 6

- AOB, summary and next steps

The Chair thanked the committee for their contribution, summarised the main actions from the

day and asked if there was any other business.

As there was no further business, the Chair highlighted the date of the next committee meeting and brought the meeting to a close.

Date of next meeting: GComm 10 - Tuesday, 8th June & Wednesday, 9th June 2021

Location of next meeting: Zoom